EMA starts rolling review of Pfizer-BioNTech variant-adapted COVID vaccine
Advertisement
New Delhi: The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday.
The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID - the original strain first identified in China, and the Omicron offshoots BA.4/5 that are currently behind most cases in Europe.
A rolling review means the EMA assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.
Last month, the EMA said it had begun a rolling review of another version of the companies' shot which targets the original SARS-CoV-2 strain and Omicron subvariant BA.1.
While existing coronavirus vaccines continue to provide good protection against hospitalisation and death, vaccine effectiveness has taken a hit as the virus has evolved.
European Union officials plan to use bivalent shots in their autumn vaccination campaign, with most cases in the region now linked to the BA.5 variant.
The EMA expects new COVID variant-adapted vaccines to be approved by September, but has signaled it is open to using shots targeting the older BA.1 variant for that campaign, given the shots targeting the newer BA.4 and BA.5 strains are further behind in clinical development.
Read also: Pfizer to purchase Global Blood Therapeutics for USD 5.4 Billion
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.